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Introduction
Endoscopic management for pain from chronic calcifying pan-
creatitis (CCP) can be achieved by draining an obstructed pan-
creatic duct (PD) and/or removing obstructing PD calculi [1].
Current guidelines recommend extracorporeal shock wave li-
thotripsy (ESWL) as first-line treatment of PD stones. However,
its limitations include lack of availability and the need for multi-
ple ESLW and endoscopic retrograde cholangiopancreatogra-
phy (ERCP) sessions [2]. The role of pancreatoscopy in PD stone
treatment is unclear, with reported success rates between 43%
and 100%, based on small retrospective studies [2–7]. In 2015,
single-operator digital video cholangiopancreaticoscopy
(SOVP) (SpyGlassDS, Boston-Scientific) was introduced. There
is limited data on the role of SOVP in the treatment of PD stones
in CP. Our aim was to investigate the role of digital SOVP-guided
PD stone lithotripsy in patients with CP with regard to safety,
technical and short-term clinical success.
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ABSTRACT
Background and study aims Endoscopic retrograde cho-
langiopancreatography (ERCP) and/or extracorporeal shock
wave lithotripsy are first-line therapies for draining an ob-
structed pancreatic duct (PD) in painful chronic calcifying
pancreatitis (CCP). Pancreaticoscopy has shown promising
success rates in small series.
Materials and methods This study was a retrospective a-
nalysis of a clinical database. Included were all digital sin-
gle-operator digital video (SOV) pancreaticoscopy-guided
interventions (n =23) on CCP patients (n =20) between
2015 and 2017. Success and complication rates were col-
lected from the database. Clinical success was determined
by assessing pain level score (NRS) and quality of life (QoL)
using standardized questionnaires.
Results Overall technical success rate (successful SOV-
pancreaticoscopy and PD drainage) was 95%. Adverse
events occurred in 7 of 23 procedures (30%) and included
extravasation from the PD (n=1), self-limiting post-sphinc-
terotomy bleeding (n=1) and post-ERCP pancreatitis (PEP)
(n =6). At 3- to 6-month follow-up, 95% of patients report-
ed improvement in symptoms and reduction in intake of
analgesics. Mean NRS decreased from 5.4 (±1.6) to 2.8
(±1.8) (P <0.01). Clinical success was achieved in 95% of pa-
tients.
Conclusions Digital SOV-guided lithotripsy was found to
be safe and effective in this highly selected population of
CCP patients. PD decompression had a beneficial effect on
pain reduction and QoL.
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Material and methods
Between 2015 and 2017, all SOVP-guided lithotripsies at two
tertiary referral centers were retrospectively identified and an-
alyzed. Inclusion criteria for SOVP were imaging-proven PD
stones with upstream dilatation and pain attributable to CCP.
Patients with prior unsuccessful ERCP or ESWL were included,
as well as patients with asymptomatic pseudocysts and pa-
tients with prior pancreatic surgery. A consensus decision to
proceed with SOVP was made by an interdisciplinary pancreatic
board at each center in shared decision with the patient. All pa-
tients meeting the inclusion criteria were consecutively and
systematically included in this retrospective study.
Exclusion criteria included age less than 18, pregnancy, ab-
dominal pain not attributable to CCP or unsuitability to receive
sedation. All patients had endoscopic ultrasound and abdomi-
nal computed tomography and/or magnetic resonance cholan-
giopancreatography prior to SOVP (▶Fig. 1). Other treatment
options (surgery, ESWL or ERCP) had already been attempted,
were deemed less suitable than SOVP or were refused by the
patient.
Conventional ERCP techniques such as balloon extraction,
mechanical lithotripsy, and balloon dilation of downstream
strictures were already used to facilitate stone removal and
stricture dilation prior to attempting SOVP in the same session.
Pancreatic sphincterotomy preceded SOVP in all cases (either
during previous or same intervention); and further treatment
of a downstream stricture (between papilla and stone) was per-
formed at the endoscopist’s discretion using a 4-mm dilatation
balloon (Hurricane RX, Boston Scientific, Nattick, Massachu-
setts, United States). SOVP was performed using 10.5 F Spy-
glassDS, which was advanced over a .035-inch guidewire (Jag-
wire, Boston-Scientific) or freehand. Lithotripsy was performed
using a Holmium:YAG-laser (AurigaXL, StarMedTech) with a
270-μm optical fiber (8Hz, 2400mJ) or electrohydraulic litho-
tripsy (EHL) utilizing either a Lithotron EL27 generator with a
2.4 F probe (Walz Elektronik, Rohrdorf, Germany) or an Autolith
tough biliary EHL system with 1.9 F probe (Northgate Technol-
ogies/Boston Scientific, Nattick, Massachusetts, United States)
with high power and maximum pulses (30) at the endoscopist’s
discretion. Intermittent PD irrigation with saline facilitated tar-
get stone visualization and lithotripsy (▶Fig. 1).
After lithotripsy, fragments were extracted using balloons or
baskets followed by pancreatic plastic stent placement (5–
10 Fr.) for prophylaxis against post-ERCP pancreatitis (PEP)
and/or PD decompression. The type/length of the PD stent
was based on the diameter, length and position of the stricture.
Prophylactic rectal nonsteroidal anti-inflammatory drugs were
administered to all patients and no prophylactic antibiotics
were administered. All patients were routinely admitted post-
SOVP for 48 hours.
The endpoints of the study were technical success, clinical
success and adverse event (AE) rates. Overall technical success
was defined by achievement of two subitems: SOVP success
and PD clearance success. SOVP success was defined as the abil-
ity to reach the target stone with SpyGlassDS. PD clearance suc-
cess was defined as PD decompression by complete PD stone
clearance or significant duct clearance making stent placement
possible.
Clinical success was defined as a >50% post-interventional
reduction on a numeric rating scale (NRS) for pain. The NRS is
a segmented numeric version of the visual analog scale (VAS)
in which a whole number (0–10) that best reflects the intensity
of their pain is chosen [8].
A systematic medical record review comprising clinical eval-
uation and biochemistry was used to determine the occurrence
of AEs [4]. AE rates and severity of AEs were reported according
to the American Society for Gastrointestinal Endoscopy guide-
lines, therefore PEP was classified by the Cotton criteria [9].
Patients were rescheduled 3 to 6 months after SOVP for
stent extraction and were also interviewed for clinical success
and quality of life using a standardized questionnaire (▶Ta-
ble 1). Statistical significance was tested with two-tailed t-test
or fisher’s exact test. A P <0.05 was considered statistically
significant. GraphPad prism 5, MS Excel and medcalc.org were
▶ Fig. 1 a Radiopaque stone in the main pancreatic duct (MPD), b wire-guided cannulation of MPD with SpyGlassDS catheter (Boston Scien-
tific, Natick, Mass, US) after pancreatic sphincterotomy, c direct visualization of the impacted stone in the pancreatic head and Electrohy-
draulic lithotripsy of the large stone.
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used as statistical tools. The study had medical ethics commit-
tee approval and written consent was obtained from all partici-
pating patients.
Results
A total of 23 interventions in 20 patients (▶Table 2) were per-
formed. Prior unsuccessful interventional procedures on pan-
creatic calculi or strictures had been performed in 95% of the
cases (▶Table 2).
Eight of 20 patients had a PD stenosis downstream to the
stone(s) and all patients had an upstream PD dilation >5mm.
SOVP success rate was achieved in 100% of cases and PD
clearance success was achieved in 19 of 20 patients (95%).
Overall technical success rate was 95%. The Holmium laser
was used in 21 interventions and EHL in 2. All EHL lithotripsies
were successful. Stone fragments could be completely re-
moved with endoscopic and fluoroscopic visualization in 13
cases (68%), whereas in six cases (32%) the stone could be suf-
ficiently reduced in size to allow for PD decompression and
stent placement, which had not been possible before. In 19 of
20 patients a plastic stent (5FR-10FR) was placed due to a per-
sistent stricture or for PEP prophylaxis. In two cases, remaining
calculi could not be detected 3 months after POP-guided litho-
tripsy, when patients underwent a subsequent ERCP for stent
extraction. In another two cases calculi could be extracted in a
subsequent intervention with standard ERCP methods. Prophy-
lactic placed stents (5FR) could be removed at next ERCP. All
eight patients with strictures still needed stenting at 6-month
follow-up. Three patients needed a stent at 3-month follow-up
due to persistent dilatation, but these stents could be extracted
at 6-month follow-up.All other patients (9 of 12; 75%) had no
stents after 3-month follow-up.
Stone location, number of stones and presence of down-
stream PD stenosis did not significantly influence success rates
(▶Table 2). AEs occurred in seven of 23 procedures (30%). In
one case, contrast extravasation from the PD was fluoroscopi-
cally identified and could be treated by temporary plastic stent-
ing in the same session. This was rated as a serious AE. The pa-
tient also developed a moderate PEP. PEP occurred in five other
procedures (total PEP rate 26%) of which four were classified as
mild and two as moderate (Cotton criteria). PEP occurred
significantly more frequently in patients with prior PEP (n =4,
P <0.01). Post-sphincterotomy bleeding occurred in one pa-
tient and was self-limiting.
Patients reported an improvement of pain 24 to 48 hours
after treatment. At 3- to 6-months follow-up, 95% of patients
reported improvement in symptoms and reduction in intake of
analgesics. One patient was lost to follow-up.Mean NRS de-
creased from 5.4 [±1.6] to 2.8 [± 1.8] (P<0.01). Clinical success
was achieved in 95% of patients. Concerning post-intervention-
al quality of life, 89% reported no or only mild disability in daily
activities and 47% described their general health status as “ex-
cellent” or “very good” afterwards.
▶ Table 1 Systematic questionnaire for follow-up (in parts adjusted
from UK SF-12 Score – Jenkinson et al. Journal of Puplic health medicine
1997).
1) How would you describe your health status in
general?
1 excellent
2 very good
3 good
4 fair
5 poor
2) How much did pain affect you in in your daily
life and work?
1 not at all
2 a little bit
3 moderately
4 very much
3) In a numerical range of 1–10 of which 10 is the
worst imaginable pain: How would you describe
your pain level at the moment?
1–10
4) The interventional procedure has reduced my
symptoms
Yes/No
5) Since the intervention my daily use of painkillers
is reduced noticeable
Yes/No
▶ Table 2 Patient data and characteristics of stone andmain pancreatic
duct.
Study details
Patients n =20 (9 female/11 male)
Age Mean ± SD=62.4 ±14.8
Time frame November 2015 to October 2017
Follow-up 3–6 months after intervention
Prior Therapies prior interventional therapies 19/20
endoscopic 17/20
ESWL 6/20 (2–4 sessions of ESWL in
each case)
prior surgery 2/20 (resection of the
pancreatic tail in both cases)
MPD Dilatation > 5mm
post concrement
20 /20
Number of stones m=1.9 (SD ±1.2)
Average size of stones 9.3mm (SD ±2.5 mm; 5– 15mm,
1– >3 stones)
Location of stones caput (n = 8), genu (n =10), corpus/tail
(n = 4)
MPD stenosis proximal
of the calculi
8/20
EWSL, extracorporeal shock wave lithotripsy; MPD, main pancreatic duct;
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Discussion
We report a high technical success rate and clinical success rate
of 95%, respectively and an acceptable AE rate of 30%, despite
the fact that we included a challenging patient population with
prior unsuccessful therapies and large PD stones. Forty percent
of patients had strictures that could be successfully treated
endoscopically in the same session, suggesting that strictures
are not an impediment to technical success.
ESWL as a standard of care has a reported success rate of
59 % to 80% after an average of three sessions and an AE rate
of 5.8% to 6.7% [10–13]. Our data suggest a potentially higher
success rate of 95%, but with a higher AE rate of 30% and oc-
currence of PEP of 26%. Due to the small cohort, no definite an-
swer can be provided as to whether laser lithotripsy or EHL is
more effective. However, it is in line with reported PEP rates in
average high-risk ERCP patients of 20.2% to 40% [14–15] and
in SOVP patients with PEP up to 28% [2, 4, 6]. Risk factors in-
clude patient-, physician- or procedure-related and are additive
[14]. Many of those factors were consistently present in our pa-
tients (e. g. prior PEP, difficult cannulation, pancreatic sphinc-
terotomy, pancreatic duct injection). Even in our small patient
cohort, a prior episode of PEP was identified as a risk factor for
PEP following SOVP (P=0.01 in Fisher’s exact test, OR 25.0,
95%-CI: 1.11 to 562.8, P=0.043). Therefore, careful patient se-
lection and an intensified PEP prophylaxis scheme, with rectal
NSAIDS and possibly PD stenting, is warranted in case of SOVP.
To our knowledge, this is the largest cohort of patients that
have been evaluated, focusing on PD stones only with digital
SOVP (SpyGlassDS). Strengths of our study include a high tech-
nical and clinical success rate, structured follow-up and a tech-
nically difficult patient population that already had failed pre-
vious treatments. Limitations of our study include its retrospec-
tive, uncontrolled design, lack of an intention-to-treat analysis,
short-term follow-up and modest number of patients. There-
fore, our results need to be interpreted cautiously given that
this was a retrospective pilot study designed primarily to assess
feasibility and safety of SOVP to treat PD stones in obstructing
CCP, and to generate information for design of future trials.
Looking at the relatively high technical and clinical success
rates, we cannot rule out the possibility that the significant
benefit of SOVP reflects an overestimation of the effect size,
due to the small sample size.
Initial endoscopic therapy (including ESWL) is likely to be in-
ferior to surgery for treatment of obstructing CCP, though a de-
finite answer will be given by the results of the ESCAPE trial.
Therefore, use of SOVP in patients with obstructive CCP due to
PD stones is limited to a small group of patients, i. e. poor surgi-
cal candidates and/or patients who refuse surgery. Direct cost
and resource comparisons are not possible due to the retro-
spective design and relatively small sample size and require as-
sessment through prospectively designed trials. The clinical
outcome regarding quality of life and pain suggests a signifi-
cant improvement in the vast majority. It remains to be seen if
these results from our small cohort can match the long-term
pain relief after ESWL in 60% to 90% of the cases [10].
Conclusion
In conclusion, SOVP-guided lithotripsy was shown to be safe
and effective also in patients with prior unsuccessful interven-
tional therapy. Complete or partial stone removal had a signifi-
cant beneficial effect on pain reduction and quality of life. Pro-
spective studies are required to validate our findings and to
help establish the role of SOVP in treatment of symptomatic
PD stones in CCP. At this stage, this treatment cannot be re-
commended as a first-line approach for fragmentation of
stones in CCP, due to its technical difficulty and the availability
of less invasive alternatives, such as ESWL.
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